FDA to weigh easing limits on unproven peptides favored by RFK Jr.

Key Points:

• The FDA plans to hold a meeting in July to consider easing restrictions on seven peptide injections, including popular ones like BPC-157, which are widely used in wellness and fitness communities but lack FDA approval and extensive safety testing.
• Health Secretary Robert F. Kennedy Jr. has advocated for loosening regulations on peptides, citing personal benefits and criticizing previous FDA moves under the Biden administration that restricted these substances due to safety concerns.
• Peptides, which are unapproved drugs often marketed for muscle building, injury healing, and anti-aging, have become popular despite being banned by sports authorities and lacking robust scientific evidence; some are sold through wellness clinics and online, sometimes illegally.
• The FDA’s previous restrictions aimed to prevent safety risks such as cancer and organ damage, but the measures faced pushback from compounding pharmacies, wellness entrepreneurs, and some members of Congress who argue that restrictions have fueled an illicit market of unregulated imports.
• The FDA meeting will review whether certain peptides should be allowed for routine compounding by pharmacies, a move that could reshape the regulatory landscape amid ongoing debates about the safety and legality of these substances.